Sclerosol

Drug overview for SCLEROSOL (talc):

Generic name: TALC
Drug class: Intrapleural Sclerosing Agents
Therapeutic class: Respiratory Therapy Agents

Talc is a sclerosing agent.

No enhanced Uses information available for this drug.

DRUG IMAGES

No Image Available

The following indications for SCLEROSOL (talc) have been approved by the FDA:

Indications:
Pleural malignant effusion

Professional Synonyms:
Malignant pleural effusion

The following dosing information is available for SCLEROSOL (talc):

Dosing
Administration
Dosing Information
Generic

No enhanced Dosing information available for this drug.

Talc is administered intrapleurally as an aerosol during thoracoscopy or open thoracotomy or as a slurry via a chest tube. Talc should not be administered IV. Prior to intrapleural administration of talc as an aerosol or slurry, effusions should be adequately drained from the pleural cavity. Success of talc pleurodesis appears to be related to completeness of the drainage of pleural fluid and full reexpansion of the lung, both of which promote symphysis of pleural surfaces.

No dosing information available.

No generic dosing information available.

The following drug interaction information is available for SCLEROSOL (talc):

Contraindicated
Severe
Moderate

There are 0 contraindications.

There are 0 severe interactions.

There are 0 moderate interactions.

The following contraindication information is available for SCLEROSOL (talc):

Overview
Contraindicated
Severe
Moderate

Drug contraindication overview.

The manufacturer states there are no known contraindications to intrapleural talc.

There are 0 contraindications.

There are 0 severe contraindications.

There are 1 moderate contraindications. Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.

Moderate List
No disease contraindications

The following adverse reaction information is available for SCLEROSOL (talc):

Overview
Severe
Less Severe

Adverse reaction overview.

The most common adverse effects reported following intrapleural administration of talc are fever and pain. Almost all reported cases of fever and over half of reported cases of pain occurred in patients who underwent diagnostic biopsies at the time of intrapleural administration of talc.

There are 6 severe adverse reactions.

More Frequent	Less Frequent
None.	None.

Rare/Very Rare
Acute respiratory distress syndrome Dyspnea Hypotension Hypovolemia Pneumonia Pulmonary thromboembolism

There are 3 less severe adverse reactions.

More Frequent	Less Frequent
None.	Fever Pain

Rare/Very Rare
Hemoptysis

The following precautions are available for SCLEROSOL (talc):

Pediatric
Pregnant
Lactation
Geriatric

Safety and efficacy of intrapleural talc have not been established in pediatric patients.

Contraindicated

None

Severe Precaution

None

Management or Monitoring Precaution

None

Category B. (See Users Guide.) There are no adequate and well-controlled studies using intrapleural talc in pregnant women; the drug should not be used during pregnancy unless benefits outweigh risks.

No enhanced Lactation information available for this drug.

Safety and efficacy of intrapleural talc in geriatric patients have not been studied specifically to date. The estimated mean and median ages of patients treated with talc slurry administered via a chest tube in clinical studies (single-arm or randomized studies) were 60 and 62 years, respectively. In other clinical studies, the mean and median ages of patients treated with intrapleural talc ranged between 50 and 62 years of age.